tbuckley/cabot-search huggingface dataset:
Case 29-2000
Authors: Mark S. Drapkin, Eugene J. Mark
Journal: New England Journal of Medicine (2000)

Presentation of CaseA 69-year-old woman was admitted to the hospital because of weakness, cough, and low-grade fever.The patient had end-stage renal disease due to membranous glomerulonephritis (Figure 1 and Figure 2) and a long history of hypertension. Four years before admission, after having undergone extracorporeal hemodialysis for three years, she received a cadaveric renal transplant, which was rejected because of the development of focal segmental glomerulosclerosis. Transplantation of a second cadaveric kidney was performed 34 months before admission. There were no episodes of rejection, and the creatinine level was approximately 2 mg per deciliter (180 μmol per liter). A chest . . .
Stat Bite : Ovarian Cancer Staging by Age
Authors: Lynn A. G. Ries
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Stat Bite : Ovarian Cancer Staging by Age Get access Lynn A. G. Ries Lynn A. G. Ries Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 7, 6 April 1994, Page 485, https://doi.org/10.1093/jnci/86.7.485 Published: 06 April 1994
Abstract C28: Binding to BCOR defines a subfamily of Psc ortholog mediated polycomb group complexes
Authors: Sarah E. Junco, Vivian J. Bardwell, Chongwoo A. Kim, Renjing Wang, Angela Robinson, Udayar Ilangovan, Alex Taylor, Micah D. Gearhart, P. John Hart, Andrew P. Hinck, Demeler Borries
Journal: Cancer Research (2011)

Abstract NSPC1 is a Polycomb group (PcG) protein that functions within a multiprotein complex containing BCOR (BCL6 Co-Repressor), a protein which has been shown to drive formation of diffuse large B cell leukemia. NSPC1 is one of six human homologs (BMI1, MEL18, NSPC1, MBLR, PCGF3 and PCGF5) of the Drosophila Polycomb group (PcG) protein Psc. While BMI1 and MEL18 can bind directly to another PcG protein called Polyhomeotic (PH), multi-protein complexes involving MBLR and NSPC1 are absent of PH and no function has yet to be assigned to PCGF3 or PCGF5. We show that the ubiquitin (Ub) fold of NSPC1 and PCGF3 does not bind PH, but instead directly interacts with a previously unrecognized 115 residue region within BCOR while the Ub folds of BMI1 and MEL18 bind only PH. Preliminary structural studies using nuclear magnetic resonance and analytical ultracentrifugation indicate that this region of BCOR can independently fold and possesses a novel structure thereby identifying this domain as a unique PcG recruiting module. Thus, we propose the presence of at least two distinct functional classes of Psc orthologs: Class I, (BMI1 and MEL18) that binds PH and Class II (PCGF3, NSPC1 and likely PCGF5) which bind BCOR. The existence of different classes of Psc homologs demonstrates the evolution of the PcG in order to diversify its silencing function. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr C28.
THU0261 Outcomes in Systemic Lupus Erythematous (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S.)
Authors: H. Kan, C. Collins, M. Dall’Era, M. B. McGuire, V. Koscielny, R. Pappu, C. Molta
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Post hoc analyses of belimumab BLISS trials identified baseline factors generally associated with high disease activity as predictors of improved response to treatment, such as SELENA-SLEDAI (SS)&gt; 10, low complement levels, anti-dsDNA positivity and glucocorticoid therapy. <h3>Objectives</h3> We examined clinical outcomes in patients with high disease activity treated with belimumab in U.S. clinical practice settings in 2012. <h3>Methods</h3> OBSErve (BLM117295) is a multicenter retrospective medical chart review study. 92 rheumatologists from U.S. non-academic centers who treat &gt;10 SLE patients annually and have &gt;5 years of practice experience were randomly recruited. Physicians randomly identified adult SLE patients who had received ≥8 infusions of belimumab as part of usual-care. Index date is the first belimumab infusion date. This post-hoc analysis was conducted among patients with low complement and high anti-dsDNA, steroids ≥7.5mg/day, and SS&gt;10 at index date. Results were reported for the 3 subgroups and the entire sample. The primary outcome was the change in overall SLE disease manifestations 6 months after index date based on physician judgement. Changes from index date in SS and oral steroid dose (when available at index date) were also analyzed. <h3>Results</h3> 501 eligible patient charts were abstracted. Key patient characteristics at index date were mean age 41.3 yrs; female 89%; Caucasian 53%, black/African American 24%, Hispanic 18%; and SLE disease duration≤5yrs 56%. 50% (n=252) had hypocomplementemia and high anti-dsDNA, 69% (n=347) had steroid dose≥7.5mg/day, and 86 (70%) out of 122 with available SS had SS&gt;10 at index date. Physician impression of overall change in disease manifestations over 6 months was similar in the subgroups of high disease activity compared to the entire sample. Within the 3 subgroups, mean SS scores decline ranged from 6.8-7.5 (51-53%), and mean steroid reduction ranged from 11.5-15.0 mg/day (58-61%) over 6 months. <h3>Conclusions</h3> Among the SLE patients with markers of high disease activity treated with at least 6 months of belimumab in clinical practice settings, clinicians observed improvement in overall SLE clinical manifestations, reduction in SELENA-SLEDAI, and reduction in steroid dose 6 months after belimumab initiation with no control arm. <h3>Disclosure of Interest</h3> H. Kan Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, C. Collins Consultant for: GlaxoSmithKline, M. Dall'Era Consultant for: GlaxoSmithKline, M. McGuire Grant/research support from: GlaxoSmithKline, V. Koscielny Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, R. Pappu Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, C. Molta Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline
Abstract 2973: Differential regulation of p21waf1 protein half-life by DNA damage and nutlin-3 in p53 wild-type tumors and its therapeutic potential
Authors: Li-Ju Chang, Alan R. Eastman
Journal: Cancer Research (2011)

Abstract DNA damage induces cell cycle arrest through both Chk1 and the p53 tumor suppressor protein, the latter arresting cells through induction of p21waf1 protein. Arrest permits cells to repair the damage and recover. The frequent loss of p53 in tumor cells makes them more dependent on Chk1 for arrest and survival. We have used the topoisomerase I inhibitor SN38 to induce DNA damage in three p53 wild-type cell lines: the immortalized MCF10A, and tumorigenic HCT116 and U2OS. Both phospho-Chk1 and p53 were elevated to a similar extent in all three cell lines. However, the HCT116 and U2OS cells exhibited far less accumulation of p21waf1 protein. The p21waf1 mRNA was induced to a similar extent, and the protein half-life was similar (∼ 30 min) in all three cell lines. These results suggest that the two tumor cell lines have a reduced rate of translation of the p21waf1 mRNA. To obtain further insight into the regulation of p21waf1, we incubated the three cell lines with the non-genotoxic drug nutlin-3, which disrupts p53:MDM2 binding thereby inducing a p53 response. Nutlin-3 induced similar levels of p53 in the three cell lines, and these levels were comparable to those seen with SN38. While nutlin-3 had little additional impact on p21waf1 induction in MCF10A cells and the half-life remained at ∼ 30 min, there was a much stronger induction in HCT116 and U2OS cells which was attributed to a much longer protein half-life (∼ 80 to 90 min). Incubation of p53 mutant cells with Chk1 inhibitors such as SCH900776 can overcome SN38-induced cell cycle arrest and drive cells through a lethal mitosis. p53 wild-type cells can be protected from this lethal mitosis through induction of p21waf1. However, the defective p21waf1 induction in HCT116 and U2OS cells is insufficient to protect them from Chk1 inhibition. In contrast, incubation with nutlin-3 induced sufficient p21waf1 that the cells arrested in either G1 or G2. This arrest protected the cells from subsequent incubation with the S phase-specific DNA damaging agents SN38 and hydroxyurea, either alone, or when combined with checkpoint inhibition. This protection was not observed in MCF10A or HCT116 cells deleted for p21waf1, or in MDA-MB-231 cells that have mutant p53. The results demonstrate that some p53 wild-type tumors have defects in p21waf1 expression, and may retain sensitivity to a combination of DNA damage plus checkpoint inhibition. Furthermore, the results suggest nutlin-3 could be used to protect normal cells from these combinations such that therapy can be targeted selectively to p53-defective tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2973. doi:10.1158/1538-7445.AM2011-2973
The Paradox of Progress
Authors: D. Carnall
Journal: BMJ (1995)

James Willis Radcliffe, pounds sterling15.50, pp 136 ISBN 1 85775 063 2

Not everything that can be counted, counts; and not everything that counts can be counted. Sir George Pickering's splendid epigram apparently graced Einstein's wall, and it is a good summary of the spirit of James Willis's personal and anecdotal foray into the philosophy of holism. The ideas in The Paradox of Progress are deceptively simple: our minds are much larger than we can ever imagine, we cannot quantify the contents of our memories. The illusion that the important things in life are quantifiable is just that: an illusion, which …
Noninvasive Ventilation for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Authors: Laurent Brochard, Jordi Mancebo, Marc Wysocki, Frédéric Lofaso, Giorgio Conti, Alain Rauss, Gérald Simonneau, Salvador Benito, Alessandro Gasparetto, François Lemaire, Daniel Isabey, Alain Harf
Journal: New England Journal of Medicine (1995)

In patients with acute exacerbations of chronic obstructive pulmonary disease, noninvasive ventilation may be used in an attempt to avoid endotracheal intubation and complications associated with mechanical ventilation.
S83 Preschool wheezing phenotypes in a representative UK birth cohort
Authors: J. M. Harris, A. Bush, N. Wilson, P. Mills, C. White, S. Moffat, L. Shread, P. Cullinan
Journal: Thorax (2010)

<h3>Introduction and objective</h3> The 2008 ERS Task Force1 recommended that preschool wheezing be classified as episodic (viral) wheeze (EVW) or multiple trigger wheeze (MTW). We investigated the relationship between these phenotypes and reported wheeze and medication use in later childhood. <h3>Methods</h3> Between 1993 and 1995, 658 consecutive mothers attending for routine ante-natal care (93% of those eligible) were recruited; they subsequently gave birth to 642 children. Detailed respiratory data were collected annually until the child reached the age of 5½ years (n=602; 94%). Further information was collected at age 8 (n=593; 92%) and 14 (n=497; 77%) years. EVW was defined as occasional wheeze in the past 12 months which occurred when the child had a cold or other infection; all other reported wheeze was defined as MTW. Using data from birth to age 5½, children were categorised as never wheezing (n=238); only EVW wheeze (n=208); both EVW and MTW wheeze (n=100) and only MTW wheeze (n=56). <h3>Results</h3> The prevalence of EVW fell from 32% at age 0–1 to 7% at age 4–5½; MTW prevalence was approximately 10% each year. Compared with never wheezers, in each wheezing group there was a higher proportion of boys (54%, 65%, 61%), (48%); p=0.02, higher exposure to ETS, and a greater prevalence of maternal and paternal asthma (p&lt;0.001, p&lt;0.001, p=0.06, respectively). Respiratory outcomes at 8 and 14 years were higher amongst the three wheezing groups, especially for those with MTW (see Abstract S83 Table 1). There was a higher prevalence of current wheeze and medication use at 8 and 14 years for those with a higher frequency of wheezing between birth and age 5½; and a lower prevalence of the same outcomes for those who only wheezed between birth and age two, compared to those who wheezed later. <h3>Conclusion</h3> At 8 and 14 years of age, never wheezers and pure EVW had lower prevalences of atopy, wheeze and current medication use than those with any MTW. These data provide external validity to the ERS phenotypes, and suggest that they provide useful prognostic information.
Successful Treatment of Disseminated Acanthamoeba Infection in an Immunocompromised Patient
Authors: Cathy A. Slater, Joshua Z. Sickel, Govinda S. Visvesvara, Rufino C. Pabico, Anthony A. Gaspari
Journal: New England Journal of Medicine (1994)

Disseminated acanthamoeba infection, an amebic infection characterized by granulomatous infiltrates in the brain and skin, usually occurs in immunocompromised or debilitated patients and generally progresses to death. There has been no effective therapy. We report on a patient who had undergone renal transplantation and was receiving triple immunosuppressive therapy when widespread granulomatous skin lesions caused by Acanthamoeba rhysodes developed. Antimicrobial therapy was initiated with a four-week course of intravenous pentamidine isethionate, topical chlorhexidine gluconate, and 2 percent ketoconazole cream. The result was a dramatic improvement in the skin lesions. Cyclosporine levels remained stable, but therapy was complicated by signs of . . .
Added Value of SPECT/CT in the Evaluation of Benign Bone Diseases of the Appendicular Skeleton
Authors: Gad Abikhzer, Saher Srour, Zohar Keidar, Rachel Bar-Shalom, Olga Kagna, Ora Israel, Daniela Militianu
Journal: Clinical Nuclear Medicine (2015)

Bone scintigraphy is a sensitive technique to detect altered bone mineralization but has limited specificity. The use of SPECT/CT has improved significantly the diagnostic accuracy of bone scintigraphy, in patients with cancer as well as in evaluation of benign bone disease. It provides precise localization and characterization of tracer-avid foci, shortens the diagnostic workup, and decreases patient anxiety. Through both the SPECT and the CT components, SPECT/CT has an incremental value in characterizing benign bone lesions, specifically in the appendicular skeleton, as illustrated by present case series.
Abstract 4777: Loss of death receptor 5 expression in plasmacytic MALT lymphoma is associated with genetic aberrations
Authors: Mariam Anees, Peter Horak, Leonhard Müllauer, Berthold Streubel, Markus Raderer, Michael Krainer
Journal: Cancer Research (2011)

Abstract Introduction: We investigated the expression profiles of TNF-Related Apoptosis Inducing Ligand (TRAIL) pathway components and the mechanisms underlying TRAIL-induced apoptosis in MALT lymphoma. In lymphoid malignancies these have been only explored in a few non Hodgkin lymphomas and in multiple myeloma so far. In view of this, we have performed a pilot study to assess the potential role of TRAIL-pathway in MALT lymphoma with and without plasmacytic differentiation. Methodology: We assessed paraffin embedded specimens from 20 patients diagnosed with MALT lymphoma and treated at the Medical University of Vienna for the expression of the key components of TRAIL pathway including TRAIL, death receptors 4 and 5 (DR4 and DR5) and the long form of the FLICE inhibitory protein (FLIPL) by immunohistochemistry. In addition, we also investigated MALT-lymphoma associated genetic aberrations including t(11;18)(q21;q21), t(14;18)(q32;q21) involving IGH and MALT1, t(1;14)(p22;q32), t(3;14)(q14;q32) involving FOXP1 and IGH and trisomies 3 and 18 by reverse transcriptase polymerase chain reaction and fluorescence in situ hybridization. Results: We observed a general loss of expression of key TRAIL components in MALT lymphomas with plasmacytic differentiation which were present in normal infiltrating plasma cells. DR4 expression was totally absent from 65.6% of the lymphoma tissues and only weakly present in the remaining 34.4%. DR5 was expressed by only 32.25% of the MALT lymphoma tissues. Out of these, DR5 was expressed by infiltrating regular plasma cells in 50% of cases, by plasmacytic lymphoma cells themselves in 40% and by both types of cells in the remaining 10%. Interestingly, MALT lymphomas expressing DR5 had a normal cytogenetic status while samples with absent or week DR5 expression displayed translocation t(11;18) and trisomy 3, 8 and/or 18. The DR5 loss was significantly correlated with cytogenetic abnormalities (R = -0.488, p=0.008). FLIPL was moderately expressed in 18.75% of our samples while TRAIL was present only in 6.25% of the tissues. Conclusion: Loss of expression of TRAIL pathway components is a common event in MALT lymphomas with plasmacytic differentiation. Moreover, DR5 expression in particular correlates with the presence of MALT-associated cytogenetic anomalies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4777. doi:10.1158/1538-7445.AM2011-4777
Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial
Authors: K. Harrington, J.-P. Machiels, S.W. Shin, E. Cohen, B. Burtness, C. Gause, A. Swift, R. Swaby, C. Le Tourneau
Journal: Annals of Oncology (2015)
FDG PET Performed at Thyroid Remnant Ablation Has a Higher Predictive Value for Long-Term Survival of High-Risk Patients With Well-Differentiated Thyroid Cancer Than Radioiodine Uptake
Authors: Florian C Gaertner, Shozo Okamoto, Tohru Shiga, Yoichi M Ito, Yuko Uchiyama, Osamu Manabe, Naoya Hattori, Nagara Tamaki
Journal: Clinical Nuclear Medicine (2015)

Purpose The predictive value of FDG PET at thyroid remnant ablation was evaluated in comparison to radioiodine uptake in high-risk patients with differentiated thyroid cancer. Patients and Methods One hundred forty-one patients who underwent radioiodine therapy (RIT) after total thyroidectomy and received at least 1 further RIT due to suspected metastases were retrospectively analyzed. Patients had not received RIT previously. FDG PET was performed before thyroid remnant ablation. Thyroid-stimulating hormone–stimulated serum thyroglobulin (Tg) was measured for biochemical response assessment (change of Tg between the first and second RIT, ΔTg). Results Biochemical response could be evaluated in 80 patients; survival data could be obtained for 88 patients (maximum, 124 months). Biochemical response was significantly better in patients with radioiodine-positive metastases compared with patients with radioiodine-negative metastases (median ΔTg I+, 55.8% vs I−, 112.6%; P < 0.01). Regarding survival, deaths occurred later in patients with radioiodine-positive metastases compared with radioiodine-negative patients; however, there was no significant difference regarding overall survival (I+, 61.3% vs I−, 58.2%; P > 0.05). Patients with FDG-positive metastases at thyroid remnant ablation showed a poorer biochemical response compared with patients with FDG-negative metastases (median ΔTg FDG+, 77.5% vs FDG−, 53.2%; P < 0.05), and these groups also differed significantly regarding survival (overall survival FDG+, 48.5% vs FDG−, 100%, P < 0.05). Conclusions At thyroid remnant ablation, FDG PET is more predictive for long-term survival, whereas radioiodine uptake is more important for short-term response. FDG PET performed at thyroid remnant ablation might represent a useful tool for management of high-risk patients with differentiated thyroid cancer.
O103 TRANSCRIPTOME ANALYSIS OF EXHAUSTED VIRUS-SPECIFIC CD8 T CELLS IN CHRONIC HBV INFECTION IDENTIFIES PROFOUND METABOLIC AND FUNCTIONAL CELL DEFECTS
Authors: P. Fisicaro, V. Barili, B. Montanini, T. Giuberti, S. Schivazappa, A. Alfieri, C. Mori, F. Bianchi, M. Massari, G. Missale, S. Ottonello, C. Ferrari
Journal: Journal of Hepatology (2014)
FRI0131 Analysis of Magnetic Resonance Imaging Scoring System for Facet Joint in Ankylosing Spondylitis
Authors: S.-K. Kim, J.-J. Kim, T.-H. Kim, K.B. Joo, S. Lee
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> The aim of this study is to identify radiographic damages at affected facet joint of the spine and also to compare radiographic inflammatory activity between facet joints and spinal disco-vertebral units (DVUs) in ankylosing spondylitis (AS). <h3>Methods</h3> The whole spine magnetic resonance imaging (MRI) from total 46 AS patients (male =38, 82.6%) were reviewed. Three different methods including the Ankylosing Spondylitis spine MRI-activity (ASspiMRI-a), the Berlin modification of the ASspiMRI-a, and the Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system for spinal inflammation were evaluated. Facet joint scoring system identified bone marrow edema, erosion, and ankylosis at the same level of each 23 DVU, which were scored between 0 to 3 points for both sides at each lesion. Total facet joint score means sum of scores of edema, erosion, and ankylosis at each level. <h3>Results</h3> Total 131 facet joint lesions, consisting of 98 for bone edema, 18 of bone erosion, and 15 of bony ankylosis, were identified. Most frequent facet joint lesions were detected at levels of C7-T1 (8.4%), T1-T2 (9.9%), L2-L3 (9.2%), and L3-L4 (9.9%) among total 131 facet joint lesions, whereas spinal inflammatory lesions were frequently identified at mid-thoracic spine level especially at T3 to T8. Total facet joint scores were closely correlated with ASspiMRI-a, Berlin, and SPARCC scores (r =0.372, p=0.011; r =0.414, p=0.004; r =0.400, p=0.006, respectively). However, the number of affected spinal joint at each DVU was not associated with that of facet joint lesions, indicating little possibility for concurrence of spinal DUVs and facet joint lesions. <h3>Conclusions</h3> This study implicates that inflammatory disease activity at facet joint was associated with that at DUVs of spine in AS. Discordance between DUVs and facet joint for concurrence of inflammation was observed. Close attention for facet joint involvement in AS should be needed. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3418
Effect of Control of Blood Glucose on Urinary Excretion of Albumin and β<sub>2</sub>Microglobulin in Insulin-Dependent Diabetes
Authors: Gian Carlo Viberti, John C. Pickup, R. John Jarrett, Harry Keen
Journal: New England Journal of Medicine (1979)

To study the effects of improved control of blood glucose on markers of renal glomerular and tubular function, we initially determined, by radioimmunoassay technics, urinary excretion rates of albumin and beta2 microglobulin in 17 nondiabetic subjects and in 43 insulin-dependent, clinically nonproteinuric diabetic patients. Duration of diabetes ranged from six months to 39 years, and the patients were studied while receiving conventional therapy. Mean urinary albumin excretion was significantly elevated in the diabetics, but beta2-microglobulin excretion rates were not different from those of the controls, suggesting that the increased albumin excretion was due to increased transglomerular loss of albumin. Seven patients with long-term diabetes (duration of six to 33 years), selected because of elevated albumin excretion, were studied before and during a continuous, subcutaneous insulin infusion for a period of one to three days. Urinary albumin excretion was significantly reduced during the insulin infusion, but mean beta2-microglobulin excretion did not change. Strict control of blood glucose, even in the short term, may reverse a functional renal abnormality in long-duration, insulin-dependent diabetes.